Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center

J BUON. 2021 Sep-Oct;26(5):2026-2032.

Authors

Sema Secilmis¹, Mehmet Sinan Dal, Merih Kizil Cakar, Alparslan Merdin, Nuran Ahu Baysal, Fevzi Altuntas

Affiliation

¹ Hematology Clinic and Bone Marrow Transplantation Unit, University of Health Sciences Ankara Dr. Abdurrahman Yurtaslan Oncology Education and Research Hospital, Ankara, Turkey.

PMID: 34761613

Abstract

Purpose: Venetoclax (VEN) is an oral selective inhibitor of antiapoptotic protein B-cell leukemia/lymphoma-2 (BCL-2).

Methods: We report 7 relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with venetoclax and hypomethylating agents (HMA).

Results: More than half of the patients could go on with venetoclax for only a few months.

Conclusion: Using venetoclax combined with HMA in R/R AML should be kept in mind as an alternative salvage option.

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Agents / therapeutic use*
Azacitidine / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Decitabine / therapeutic use*
Drug Combinations
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Male
Methyltransferases / antagonists & inhibitors*
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Sulfonamides / therapeutic use*
Young Adult

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Drug Combinations
Sulfonamides
Decitabine
Methyltransferases
Azacitidine
venetoclax